Cat. No.: DAB-0011906
Product Information | |
---|---|
Clonality | Polyclonal |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB |
Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn507 of human COL1A2 protein. Antibodies are purified by peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | COL1A2 |
UniProt No. | P08123 |
Gene ID | 1278 |
Gene Description | Type 1 collagen is the most abundant collagen in many human tissues, including bone, skin, and tendons. It is a trimeric complex comprised of two molecules of COL1A1 and one molecule of COL1A2. The loss-of-function mutations in the COL1A1 and COL1A2 genes are a major causative factor for osteogenesis imperfecta. Notably, COL1A2 expression levels have also been associated with tumor development in gastric cancer, pancreatic cancer, and chondrosarcoma. Research studies suggest that upregulation of COL1A2 can generate a modified extracellular matrix environment that promotes cancer cell proliferation, migration, and invasion. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.